Thyrocare Technologies Ltd (IN:THYROCARE)
:THYROCARE
Want to see IN:THYROCARE full AI Analyst Report?
THYROCARE Stock Chart & Stats
₹459.10
-₹16.20(-1.70%)
At close: 4:00 PM EST
₹459.10
-₹16.20(-1.70%)
Day’s Range― - ―
52-Week Range₹290.00 - ₹537.97
Previous CloseN/A
Volume114.81K
Average Volume (3M)56.30K
Market Cap
₹64.31B
Enterprise Value₹20.99B
Total Cash (Recent Filing)₹1.92B
Total Debt (Recent Filing)₹246.80M
Price to Earnings (P/E)61.2
Beta0.55
Next Earnings
May 21, 2026EPS Estimate
5.4Next Dividend Ex-DateN/A
Dividend Yield0.68%
Share Statistics
EPS (TTM)4.30
Shares Outstanding159,165,310
10 Day Avg. Volume44,587
30 Day Avg. Volume56,302
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)2.35
Price to Sales (P/S)1.87
P/FCF Ratio8.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.1
Revenue Forecast (FY)₹9.48B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained ~21% revenue growth indicates expanding test volumes and stronger market penetration. Over a 2–6 month horizon this supports scale benefits for centralized labs, underpins pricing leverage on test bundles, and provides a durable top-line base for reinvestment and margin recovery.
Cash Flow QualityImproving operating cash flow and positive free cash flow growth reflect high-quality earnings and self-funded operations. This durable cash generation allows the company to fund capex, absorb demand variability, and invest in automation or distribution without immediate external financing.
Balance Sheet StrengthA low leverage profile with an improving equity ratio provides financial flexibility and lowers refinancing risk. This durable balance sheet strength supports strategic initiatives, potential M&A or capacity expansion, and cushions the business during cyclical test-volume fluctuations.
Bears Say
Margin PressureA declining net margin suggests rising operating costs or higher financial charges that could persist. If structural cost inflation or pricing pressure continues, margins may compress, reducing free cash flow and curtailing the firm's ability to invest or return capital without efficiency gains.
Significant CapExSustained high capital expenditures can materially absorb operating cash flow and limit flexibility, especially if revenue growth moderates. Over 2–6 months, elevated capex commitments could strain liquidity or delay returns unless matched by continued volume growth or improved capex efficiency.
Revenue Concentration RiskDependence on test volumes routed through collection partners and centralized lab throughput concentrates operational risk. Competitive pressures, partner disruption, or volume declines could disproportionately impact utilization, unit economics and long-term revenue visibility without diversification.
Thyrocare Technologies Ltd News
THYROCARE FAQ
What was Thyrocare Technologies Ltd’s price range in the past 12 months?
Thyrocare Technologies Ltd lowest stock price was ₹290.00 and its highest was ₹537.97 in the past 12 months.
What is Thyrocare Technologies Ltd’s market cap?
Thyrocare Technologies Ltd’s market cap is ₹64.31B.
When is Thyrocare Technologies Ltd’s upcoming earnings report date?
Thyrocare Technologies Ltd’s upcoming earnings report date is May 21, 2026 which is in 21 days.
How were Thyrocare Technologies Ltd’s earnings last quarter?
Thyrocare Technologies Ltd released its earnings results on Jan 28, 2026. The company reported ₹4.3 earnings per share for the quarter, missing the consensus estimate of ₹4.5 by -₹0.2.
Is Thyrocare Technologies Ltd overvalued?
According to Wall Street analysts Thyrocare Technologies Ltd’s price is currently Overvalued.
Does Thyrocare Technologies Ltd pay dividends?
Thyrocare Technologies Ltd pays a Quarterly dividend of ₹2.333 which represents an annual dividend yield of 0.68%. See more information on Thyrocare Technologies Ltd dividends here
What is Thyrocare Technologies Ltd’s EPS estimate?
Thyrocare Technologies Ltd’s EPS estimate is 5.4.
How many shares outstanding does Thyrocare Technologies Ltd have?
Thyrocare Technologies Ltd has 159,165,310 shares outstanding.
What happened to Thyrocare Technologies Ltd’s price movement after its last earnings report?
Thyrocare Technologies Ltd reported an EPS of ₹4.3 in its last earnings report, missing expectations of ₹4.5. Following the earnings report the stock price went up 1.313%.
Which hedge fund is a major shareholder of Thyrocare Technologies Ltd?
Currently, no hedge funds are holding shares in IN:THYROCARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Thyrocare Technologies Ltd
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates in three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical diagnostic tests and profiles of tests that focuses on early detection and management of disorders and diseases, including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility, COVID, and various infectious diseases. Its profiles of tests include 34 profiles of tests administered under its Aarogyam brand, which offers patients a suite of wellness and preventive health care tests. The company also sells glucometer and glucostrips under the brand name Sugarscan; consumables; and radiopharmaceutical. Thyrocare Technologies Limited was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.
Technical Analysis
Krsnaa Diagnostics Limited
―
Medi Assist Healthcare Services Limited
―
Metropolis Healthcare Ltd.
―
Morepen Laboratories Limited
―
Vijaya Diagnostic Centre Ltd.
―